A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with autologous T cell receptor gamma-chain alternate reading frame protein (TARP) peptide with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous TARP peptide-pulsed dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is commonly expressed in breast and prostate cancer cells.
Leave a Comment
You must be logged in to post a comment.